BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35909569)

  • 21. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib.
    Taylor MH; Takahashi S; Capdevila J; Tahara M; Leboulleux S; Kiyota N; Dutcus CE; Xie R; Robinson B; Sherman S; Habra MA; Elisei R; Wirth LJ
    Thyroid; 2021 Aug; 31(8):1226-1234. PubMed ID: 33637020
    [No Abstract]   [Full Text] [Related]  

  • 22. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
    Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
    Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
    [No Abstract]   [Full Text] [Related]  

  • 23. Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer.
    Lin Y; Qin S; Yang H; Shi F; Yang A; Han X; Liu B; Li Z; Ji Q; Tang L; Deng Z; Ding Y; Fu W; Xie X; Li L; He X; Lv Z; Ma Q; Shen Z; Guo Z; Chen Z; Cui Y; Tan J; Gao Z; Jing S; Lu K; Luo X; Zhang Y; Fang Y; Li Z; Cheng Y; Lei S; Luan S; Chen G; Wang G; Wu L; Liu L
    Clin Cancer Res; 2023 Aug; 29(15):2791-2799. PubMed ID: 37184934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer.
    Chen HD; Zhou J; Wen F; Zhang PF; Zhou KX; Zheng HR; Yang Y; Li Q
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):361-368. PubMed ID: 27798730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.
    Locati LD; Piovesan A; Durante C; Bregni M; Castagna MG; Zovato S; Giusti M; Ibrahim T; Puxeddu E; Fedele G; Pellegriti G; Rinaldi G; Giuffrida D; Verderame F; Bertolini F; Bergamini C; Nervo A; Grani G; Rizzati S; Morelli S; Puliafito I; Elisei R
    Eur J Cancer; 2019 Sep; 118():35-40. PubMed ID: 31299580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
    Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
    Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
    [No Abstract]   [Full Text] [Related]  

  • 27. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
    Schlumberger M; Tahara M; Wirth LJ; Robinson B; Brose MS; Elisei R; Habra MA; Newbold K; Shah MH; Hoff AO; Gianoukakis AG; Kiyota N; Taylor MH; Kim SB; Krzyzanowska MK; Dutcus CE; de las Heras B; Zhu J; Sherman SI
    N Engl J Med; 2015 Feb; 372(7):621-30. PubMed ID: 25671254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis.
    Liu K; Zhu Y; Zhu H
    Front Immunol; 2022; 13():1103055. PubMed ID: 36713376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid.
    Tahara M; Schlumberger M; Elisei R; Habra MA; Kiyota N; Paschke R; Dutcus CE; Hihara T; McGrath S; Matijevic M; Kadowaki T; Funahashi Y; Sherman SI
    Eur J Cancer; 2017 Apr; 75():213-221. PubMed ID: 28237867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences.
    Masaki C; Sugino K; Saito N; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
    Thyroid; 2020 Feb; 30(2):214-221. PubMed ID: 31854270
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacological and clinical profile of lenvatinib (E-7080) in the treatment of advanced, radioiodine-refractory, differentiated thyroid cancer.
    Hegazi M; Azadi A; Jain D; Redman R; Perez CA
    Drugs Today (Barc); 2015 Dec; 51(12):689-94. PubMed ID: 26798849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer.
    Lin Y; Wang C; Gao W; Cui R; Liang J
    Oncotarget; 2017 Jun; 8(26):42252-42261. PubMed ID: 28178685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
    Goto H; Kiyota N; Otsuki N; Imamura Y; Chayahara N; Suto H; Nagatani Y; Toyoda M; Mukohara T; Nibu KI; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
    Auris Nasus Larynx; 2018 Dec; 45(6):1249-1252. PubMed ID: 29779695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
    Yeung KT; Cohen EE
    Clin Cancer Res; 2015 Dec; 21(24):5420-6. PubMed ID: 26487760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
    Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
    Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer.
    Brose MS; Nutting CM; Sherman SI; Shong YK; Smit JW; Reike G; Chung J; Kalmus J; Kappeler C; Schlumberger M
    BMC Cancer; 2011 Aug; 11():349. PubMed ID: 21834960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer.
    Silaghi H; Lozovanu V; Georgescu CE; Pop C; Nasui BA; Cătoi AF; Silaghi CA
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.
    Tahara M; Brose MS; Wirth LJ; Suzuki T; Miyagishi H; Fujino K; Dutcus CE; Gianoukakis A
    Eur J Cancer; 2019 Jan; 106():61-68. PubMed ID: 30471649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
    Teng MM; Chen SY; Yang B; Wang Y; Han RY; An MN; Dong YL; You HS
    Cancer Med; 2021 Sep; 10(18):6344-6353. PubMed ID: 34382361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patients.
    Fukuda N; Toda K; Udagawa S; Ohmoto A; Oki R; Suto H; Wang X; Hayashi N; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
    Endocrine; 2022 Apr; 76(1):70-77. PubMed ID: 35088293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.